CUMYL-NBMINACA

Cumyl-NBMINACA is a synthetic cannabinoid of the indazole-3-carboxamide family, a full agonist at the CB1 cannabinoid receptor. Pulver et al. (2023) report, for the norbornylmethyl series, an affinity constant Ki between 0.25 and 1.87 nM, the indazole being the most affine derivative, with an EC50 from 1.78 to 169 nM for the same series. Giorgetti et al. (2025) described its phase I metabolism from two authentic urine samples, in which 13 phase I metabolites were identified, and proposed urinary biomarkers based on the norbornylmethyl chain. Its legal status in France remains to be settled: it is not named on the ANSM list, and whether it meets the generic definition of indazole-3-carboxamides depends on how the cycloalkylmethyl substituent is interpreted. No clinical study and no controlled human toxicology data are published in the sources consulted.

Source

Synthetic molecule: the sources consulted class it among synthetic cannabinoids, with no plant origin reported in those sources. Purified standards of Cumyl-NBMINACA were isolated from herbal blend material within the European ADEBAR plus project (Giorgetti et al., 2025). Pulver et al. (2023) report that the cyclobutylmethyl and norbornylmethyl side chains allowed these substances to circumvent German legislation, and that the market life cycle of these substances was less than one year.

No biosynthetic pathway: Cumyl-NBMINACA is a synthetic molecule, chemically classed among the indazole-3-carboxamides, with no known link to a plant or a living organism.

European Union

At European Union level, no harmonised control measure is documented in the sources consulted: control falls under national legislation.

France

Cumyl-NBMINACA is not named on the ANSM consolidated list of narcotics (updated 16 February 2026). The relevant framework is the generic definition of indazole-3-carboxamide derivatives, listed in annex IV of that consolidated list. The amide condition is met: the cumyl group is among the listed substituents. The condition on the N1 nitrogen requires a cycloalkylmethyl-type substituent, and the norbornylmethyl chain is a bicyclic ring: the text does not say whether this case falls within that category. As this cannot be decided with certainty, the French status is classed as evolving. The international status is separate: the compound is not listed on the INCB Green List 2026.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

1. 1Giorgetti et coll., métabolisme de phase I humain de trois cannabinoïdes de synthèse à noyau cumyle dont le Cumyl-NBMINACA, Drug Test Anal, 2025 (new tab)PMID 39218806
2. 2Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des cannabinoïdes de synthèse à chaînes cyclobutylméthyle et norbornylméthyle, Drug Test Anal, 2023 (new tab)PMID 36541839
3. 3ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, définition des dérivés du 3-carboxamide indazole) (new tab)
4. 4OICS, Liste verte des substances psychotropes sous contrôle international, édition 2026 (new tab)
5. 5PubChem, CUMYL-NBMINACA, CID 117650372 (new tab)

SMILES

CC(C)(C1=CC=CC=C1)NC(=O)C2=NN(C3=CC=CC=C32)CC4CC5CCC4C5

InChIKey

MLRLLZWQYJJPEX-UHFFFAOYSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.